

## **REMARKS**

### **Introduction**

Claims 1-2, 9 and 11 are pending. Claim 1 has been amended. Support for this amendment can be found throughout the specification, for example, at paragraph [0010] and in the claims as filed. No new matter has been added.

Claims 3-8 and 10 have been cancelled without prejudice to the subject matter disclosed therein. Applicant expressly reserves the right to pursue this subject matter in other applications or in this application via rejoinder.

### **Examiner Interview on May 6, 2007**

Applicant wishes to thank the Examiner and her supervisor for the courtesy of interviewing this case. Further to the discussion, Applicant has amended the claims in accord with the language for which agreement was reached during the interview.

### **Rejection under 35 U.S.C. §112**

The Examiner has rejected claims 1, 2, 9, and 11 under 35 U.S.C. §112 second paragraph as allegedly failing to point out and distinctly claim the subject matter that Applicant regards as the invention. Specifically, the Examiner asserts that the phrase "having a reduced prekallikrein content" as recited in claim 1 is allegedly indefinite. Applicant respectfully traverses.

To expedite prosecution, Applicant has amended claim 1 to reflect the agreed upon language from the Examiner Interview of May 6, 2007. This rejection is now moot. Accordingly, Applicant respectfully requests withdrawal of the rejection under 35 U.S.C. § 112.


**CONCLUSION**

All of the stated grounds of objection and rejection have been properly traversed, accommodated, or rendered moot. Applicants therefore respectfully request that the Examiner reconsider all presently outstanding objections and rejections and that they be withdrawn. Applicants believe that a full and complete reply has been made to the outstanding Office Action and, as such, the present application is in condition for allowance. Accordingly, Applicants request that the Examiner issue a Notice of Allowance indicating the allowability of claims 1, 2, 9, and 11 and that the application be passed to issue. If the Examiner believes, for any reason, that personal communication will expedite prosecution of this application, the Examiner is hereby invited to telephone the undersigned at the number provided.

The Commissioner is authorized to charge any deficiency in any patent application processing fees pursuant to 37 CFR §1.17, including extension of time fees pursuant to 37 CFR §1.17(a)-(d), associated with this communication and to credit any excess payment to Deposit Account No. 22-0261.

Dated: May 7, 2008

Respectfully submitted,

By   
Matthew E. Kelley  
Registration No.: 55,887  
VENABLE LLP  
P.O. Box 34385  
Washington, DC 20043-9998  
(202) 344-4000  
(202) 344-8300 (Fax)  
Attorney/Agent For Applicant